Genesis Molecular AI
Genesis Therapeutics provides an AI platform for drug discovery that combines foundation models with physics-based approaches to tackle challenging biological targets. The platform, anchored by GEMS as an AI operating system for molecular design, integrates virtual design with experimental validation in iterative cycles that continuously improve predictive capabilities. Its Pearl foundation model, introduced in October 2025, powers both internal drug programs and those of major pharmaceutical partners.
- Drug Discovery & Therapeutics
- Artificial Intelligence
- Biotechnology
- Software Only
Funding
Funding not disclosed
Founders
Founder details are not available yet.
Product
Problem
Drug discovery faces significant challenges when targeting difficult or complex biological targets, where traditional computational and experimental methods often fall short. These challenging targets require more sophisticated molecular design approaches that can navigate vast chemical space and accurately predict therapeutic potential before costly experimental validation.
Solution
Genesis Therapeutics provides an AI platform for drug discovery that uses foundation models and an operating system for molecular design to tackle challenging drug targets. The platform, anchored by GEMS as an AI operating system for molecular design, integrates virtual design with experimental validation in iterative cycles. Each cycle on every program generates new data that feeds back into the AI model, continuously improving its predictive capabilities and design accuracy. The platform powers both Genesis's own drug programs and those of major pharmaceutical partners, working through interdisciplinary loops that combine AI research with biotech expertise to solve the hardest problems in drug discovery.
Target Audience
Primary customers are biopharmaceutical companies seeking to accelerate drug discovery for challenging targets, as well as internal drug discovery programs focused on novel therapeutics.
Features
- GEMS, an AI operating system for molecular design, serving as the central platform for structure-based and ligand-based drug discovery workflows
- Pearl, a next-generation foundation model specifically developed for drug discovery applications, announced in October 2025
- Zero-shot Pearl system that surpasses all cofolding models on OpenBind, demonstrating advanced predictive capabilities without task-specific training
- Model distillation capabilities that enhance model efficiency and deployment, announced in June 2026
- Integrated virtual-to-validation pipeline that connects computational molecular design with experimental testing in a closed feedback loop
- Iterative learning architecture where every program cycle produces new data that directly improves AI model capabilities across all programs